0000000000667803
AUTHOR
Diana González-bermejo
[Clinical equipoise and systematic reviews of randomized controlled trials].
.Para poder valorar la validez de un ensayo cli´nico es necesarioque su disen˜o, ejecucio´n y ana´lisis se describan con suficientedetalle, exactitudytransparencia.Sinembargo,existennumerososejemplos en la literatura cienti´fica que ponen de manifiesto co´mola informacio´n facilitada en las publicaciones es muchas vecesdeficiente, y que con frecuencia se presentan problemas metodo-lo´gicos graves
Additional file 1: of The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review
Reporting methods and results of CEA Spain_annex. Table S1. PubMed/MEDLINE search strategy. Table S2. Included studies. Table S3. PRISMA Checklist. Figure S1. Flow diagram for study selection. Figure S2. Growth in published cost-effectiveness analyses. Spain, 1989-2014.
The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review
Open Access; Open Peer Review.-- et al.
Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
Background Medications aimed at inhibiting the renin–angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. Methods and Findings Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. T…